Author Topic: Ocrelizumab and liver injury research information (PubMed)  (Read 5 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8282
  • MS diagnosed 1980
  • Location: Pacific Northwest
Ocrelizumab and liver injury research information (PubMed)
« on: November 04, 2019, 02:43:44 pm »

The Overview section of the report on Ocrevus that is part of a larger report entitled  LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, issued by the National Institute of Diabetes and Digestive and Kidney Diseases. This section was last updated in July 2018.

https://www.ncbi.nlm.nih.gov/books/NBK548145/#Ocrelizumab.OVERVIEW



The "likelihood score" for Ocrevus is E*, which is defined as:


Quote
Category E*. The drug is suspected to be capable of causing liver injury or idiosyncratic acute liver injury but there have been no convincing cases in the medical literature. In some situations cases of acute liver injury have been reported to regulatory agencies or mentioned in large clinical studies of the drug, but the specifics and details supportive of causality assessment are not available. The agent is unproven, but suspected to cause liver injury.
« Last Edit: November 04, 2019, 02:54:00 pm by agate »
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
7 Views
Last post October 24, 2019, 04:29:04 pm
by agate
0 Replies
3 Views
Last post October 25, 2019, 07:56:09 pm
by agate
0 Replies
7 Views
Last post October 26, 2019, 03:31:32 pm
by agate
0 Replies
8 Views
Last post October 28, 2019, 04:12:17 pm
by agate
0 Replies
3 Views
Last post November 01, 2019, 06:08:19 pm
by agate